freeze-thaw raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-14 and is reviewed periodically as new material appears.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Parent peptide; salt forms also reported |
| Molecular mass | about 4113.6 Da | Average mass of the free peptide |
| Peptide length | 31 amino acids | Backbone related to GLP-1(7-37) |
| Key substitution | Aib at position 8 | Blocks DPP-4 cleavage |
| Albumin binding | Via C-18 diacid side chain | Prolongs circulation time |
Stability studies examine how temperature, pH, and moisture influence degradation rates over time. In aqueous solution, hydrolysis and deamidation accelerate as pH moves away from mildly acidic conditions. Light exposure and residual metal ions can also trigger oxidation of susceptible residues. Accelerated aging at elevated temperature is used to estimate shelf life, though extrapolation to room temperature carries uncertainty because individual degradation pathways do not always scale predictably.
Lyophilized semaglutide powder is typically held at minus twenty degrees Celsius for long-term storage. At that temperature, solid-state degradation reactions proceed slowly and the peptide remains intact for extended periods. Repeated freeze-thaw cycles are best avoided because they promote aggregation and can shift the proportion of monomeric peptide present. Working aliquots are often prepared so that each portion is thawed only once, and desiccant is placed inside the vial to limit moisture uptake.
Identity and purity are usually assessed by reverse-phase high-performance liquid chromatography coupled to mass spectrometry. Retention time and observed mass are compared against a reference standard run under identical conditions. Impurity profiles reveal deamidation products, oxidized methionine variants, and truncated fragments that arise during synthesis or storage. Peptide mapping through enzymatic digestion confirms the primary sequence, while amino acid analysis offers an independent check on overall composition.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
The semaglutide sequence is a 31-residue analogue of human GLP-1, altered at three positions relative to the parent hormone. Aminoisobutyric acid replaces alanine at position 8, arginine replaces lysine at position 34, and a lipophilic diacid is attached to lysine 26 through a short linker. These features are reported consistently in the structural literature. The position 8 substitution blocks recognition by dipeptidyl peptidase-4, while the attached chain drives strong, reversible association with a carrier protein in blood.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
== Taxonomy == Carl Linnaeus described the species in 1771, the specific epithet biloba derived from the Latin bis, "twice" and loba, "lobed", referring to the shape of the leaves. Two names for the species recognise the botanist Richard Salisbury, a placement by Nelson as Pterophyllus salisburiensis and the earlier Salisburia adiantifolia proposed by James Edward Smith. The epithet of the latter may have been intended to denote a characteristic resembling Adiantum, the genus of maidenhair ferns. The generic name Ginkgo can be traced to recordings done by Engelbert Kaempfer, the first Westerner to investigate the species in 1690 in Nagasaki, for the Amoenitates Exoticae (1712): it is regarded as a mistranscription of Japanese 銀杏 ginkyō ([ɡiŋkʲoː]). Taking his spelling of other Japanese words containing the syllable [kʲoː] (present romanization: kyō) into account, an expected transcription would have been "ginkio" or "ginkjo". Thus, his curious "–kgo" spelling has long been considered to be an error Kaempfer made in his notes, but Nagata et al. showed that it was the spelling of his interpreter, Genemon Imamura, who spoke the local Nagasaki dialect. Linnaeus adopted the ginkgo spelling based on Kaempfer's compilation of Japanese flora in Amoenitates while writing Mantissa plantarum II (Amoenitates Exoticae, p. 811) thus becoming the tree's generic name. Kaempfer's drawing can be found in Hori's article.
=== Elimination === Alcohol is removed from the bloodstream by a combination of metabolism, excretion, and evaporation. 90-98% of ingested ethanol is metabolized into carbon dioxide and water. Around 5 to 10% of ethanol that is ingested is excreted unchanged in urine, breath, and sweat. Transdermal alcohol that diffuses through the skin as insensible perspiration or is exuded as sweat (sensible perspiration) can be detected using wearable sensor technology such as SCRAM ankle bracelet or the more discreet ION Wearable. Ethanol or its metabolites may be detectable in urine for up to 96 hours (3–5 days) after ingestion. Unlike most physiologically active materials, in typical recreational use, ethanol is removed from the bloodstream at an approximately constant rate (linear decay or zero-order kinetics), rather than at a rate proportional to the current concentration (exponential decay with a characteristic elimination half-life). This is because typical doses of alcohol saturate the enzymes' capacity. In Widmark's model, the elimination rate from the blood, β, contributes 60% of the uncertainty. Similarly to ρ, its value depends on the units used for blood. β varies 58% by occasion and 42% between subjects; it is thus difficult to determine β precisely, and more practical to use a mean and a range of values. Typical elimination rates range from 10 to 34 mg/dL per hour, with Jones recommending the range 0.10 - 0.25 g/L/h for forensic purposes, for all subjects.
This broad classification is based on the empirical makeup and atomic structure of the solid materials, and most solids fall into one of these broad categories. An item that is often made from each of these materials types is the beverage container. The material types used for beverage containers accordingly provide different advantages and disadvantages, depending on the material used. Ceramic (glass) containers are optically transparent, impervious to the passage of carbon dioxide, relatively inexpensive, and are easily recycled, but are also heavy and fracture easily. Metal (aluminum alloy) is relatively strong, is a good barrier to the diffusion of carbon dioxide, and is easily recycled. However, the cans are opaque, expensive to produce, and are easily dented and punctured. Polymers (polyethylene plastic) are relatively strong, can be optically transparent, are inexpensive and lightweight, and can be recyclable, but are not as impervious to the passage of carbon dioxide as aluminum and glass.
Medical licensure in the United States is governed by state boards of medicine. In most states, graduates of US medical schools may obtain a full medical license after passage of the third step of the United States Medical Licensing Examination (USMLE), and at least one year of postgraduate education—i.e. one year of residency; usually called an internship. However, in most states, international medical graduates are required longer periods of training as well as passage of the third and final step of the USMLE, to obtain a full medical license. Physicians who have full medical licenses may practice medicine without supervision ("moonlight") in settings such as urgent care clinics and rural hospitals while in residency. However, while performing the requirements of their residency, residents are supervised by attending physicians who must approve their decisions.
== Publications == Phil S. Baran has authored and co-authored approximately 300 research publications with an h-index of 133 and over 60,000 citations. His group's research has been published in journals including Science, Nature, Journal of American Chemical Society (JACS), Angewandte Chemie, and Journal of Organic Chemistry (JOC). Baran has authored the digital interactive reference text The Portable Chemist's Consultant: A Survival Guide for Discovery, Process, and Radiolabeling and contributed chapters and forewords to several scientific publications.
Sources: en.wikipedia.org
== Side effects == Possible side effects of olanzapine/fluoxetine include all those of the two component drugs: olanzapine (side effects) and fluoxetine (side effects). Common side effects include suicidal thoughts, increased appetite, weight gain, drowsiness, fatigue, dry mouth, swelling, tremor, blurred vision, and difficulty concentrating. Olanzapine/fluoxetine could produce a severe allergic reaction and should not be used if the patient has previously experienced an allergic reaction to either fluoxetine or olanzapine. Olanzapine is correlated with an increase in blood sugar. Patients with diabetes, or those at risk for developing it, require careful monitoring. In rare cases, olanzapine/fluoxetine may cause neuroleptic malignant syndrome. Like other SSRIs, olanzapine/fluoxetine carries a boxed warning stating that it could increase the risk of suicidal thoughts and behaviors in patients aged 24 and under. The warning also states that olanzapine/fluoxetine may increase the risk of death in elderly patients with dementia-related psychosis.
On October 2, he participated in the vice-presidential debate with Palin at Washington University in St. Louis. Post-debate polls found that while Palin exceeded many voters' expectations, Biden had still won the debate overall. On November 4, Obama and Biden were elected. As Biden was running for vice president, he was also running for reelection to the Senate, as permitted by Delaware law. Having been reelected to the Senate as well as the vice presidency, Biden made a point of not resigning from the Senate before he was sworn in for his seventh term in January 2009. He resigned from the Senate on January 15.
LC-MS is particularly amenable to detecting hydrophobic molecules (lipids, fatty acids) and peptides while GC-MS is best for detecting small molecules (<500 Da) and highly volatile compounds (esters, amines, ketones, alkanes, thiols). Unlike the genome or even the proteome, the metabolome is a highly dynamic entity that can change dramatically, over a period of just seconds or minutes. As a result, there is growing interest in measuring metabolites over multiple time periods or over short time intervals using modified versions of NMR or MS-based metabolomics.
=== Scope and related laser-based procedures === LANAP is commonly described as a wavelength-dependent, flapless periodontal pocket treatment protocol performed with an Nd:YAG laser (1064 nm). Other minimally invasive or adjunctive laser approaches to periodontal and peri-implant pocket therapy using different wavelengths have been described and are distinct from LANAP. A review reports that CO2 laser systems share soft-tissue applications with diode and Nd:YAG lasers (bacterial reduction, debridement in pockets and around implants, and coagulation), but that clinical studies and meta-analyses have not consistently shown statistically significant improvements versus mechanical debridement alone. For peri-implant diseases, an AAP best-evidence review and meta-analysis reported that laser therapy in combination with surgical or non-surgical therapy provided minimal benefit for several clinical outcomes, and noted that the controlled evidence included in the analyses was limited to Er:YAG, CO2 laser, and diode lasers. In 2016, the FDA cleared labeling for an Nd:YAG system that included an indication describing “promotion of true regeneration” (new cementum, periodontal ligament, and alveolar bone) when used specifically in the LANAP protocol. A 2017 review concluded that studies of lasers in the treatment of periodontitis had not provided sufficient evidence that laser use provides benefit over traditional therapy.
=== Cardiac conditions === Subtypes of troponin (cardiac I and T) are sensitive and specific indicators of heart muscle damage (myocardium). They are measured in the blood to differentiate between unstable angina and myocardial infarction (heart attack) in people with chest pain or acute coronary syndrome. A person who recently had a myocardial infarction has areas of damaged heart muscle and elevated cardiac troponin levels in the blood. This can also occur in people with coronary vasospasm, a type of myocardial infarction involving severe constriction of the cardiac blood vessels. After a myocardial infarction troponins may remain high for up to 2 weeks. Cardiac troponins are a marker of all heart muscle damage, not just myocardial infarction, which is the most severe form of heart disorder. However, diagnostic criteria for raised troponin indicating myocardial infarction is currently set by the WHO at a threshold of 2 μg/L or higher. Critical levels of other cardiac biomarkers are also relevant, such as creatine kinase. Severe tachycardia (for example due to supraventricular tachycardia) in an individual with normal coronary arteries can also lead to increased troponins for example, it is presumed due to increased oxygen demand and inadequate supply to the heart muscle. Coronary artery stent placement can also cause immediate post-procedure elevated serum cardiac troponin levels. This can be problematic in a clinical setting as troponin values and guidance protocols become subject to more thoughtful interpretation.
Sources: en.wikipedia.org
After scoring a hit with the recording, he looked to Cornelius to help him put together an actual group to maintain the impact. In 1977, Soul Train dancers Jody Watley and Jeffrey Daniels and former Soul Train Gang member Gerald Brown (who was eventually replaced by Howard Hewett) were recruited to form the new Shalamar, which would become the fledgling label's centerpiece. Cornelius wanted to shut down the label and Griffey paid him $300,000 for his interests in the label. Cornelius wanted to focus his energies on the TV show — which was a monster hit and required his full attention to keep it so. With legalities now taken care of, Griffey reorganized Soul Train Records into the newly founded SOLAR label in late 1977. Griffey and Cornelius remained good friends, and as a result SOLAR maintained close ties to the Soul Train show.
== Chemistry == Several chemical factors affect the ionophore activity. The activity of an ionophore-metal complex depends on its geometric configuration and the coordinating sites and atoms which create coordination environment surrounding the metal center. This affects the selectivity and affinity towards a certain ion. Ionophores can be selective to a particular ion but may not be exclusive to it. Ionophores facilitate the transport of ions across biological membranes most commonly via passive transport, which is affected by lipophilicity of the ionophore molecule. The increase in lipophilicity of the ionophore-metal complex enhances its permeability through lipophilic membranes. The hydrophobicity and hydrophilicity of the complex also determines whether it will slow down or ease the transport of metal ions into cell compartments. The reduction potential of a metal complex influences its thermodynamic stability and affects its reactivity. The ability of an ionophore to transfer ions is also affected by the temperature.
== Histological staining == In the clinical setting, amyloid diseases are typically identified by a change in the spectroscopic properties of planar aromatic dyes such as thioflavin T, congo red or NIAD-4. In general, this is attributed to the environmental change, as these dyes intercalate between β-strands to confine their structure. Congo Red positivity remains the gold standard for diagnosis of amyloidosis. In general, binding of Congo Red to amyloid plaques produces a typical apple-green birefringence when viewed under cross-polarized light. Recently, significant enhancement of fluorescence quantum yield of NIAD-4 was exploited to super-resolution fluorescence imaging of amyloid fibrils and oligomers. To avoid nonspecific staining, other histology stains, such as the hematoxylin and eosin stain, are used to quench the dyes' activity in other places such as the nucleus, where the dye might bind. Modern antibody technology and immunohistochemistry has made specific staining easier, but often this can cause trouble because epitopes can be concealed in the amyloid fold; in general, an amyloid protein structure is a different conformation from the one that the antibody recognizes.
== Rheumatism, excluding the back (725–729) == 725 Polymyalgia rheumatica 726 Peripheral enthesopathies and allied syndromes 726.0 Adhesive capsulitis, shoulder 726.1 Rotator cuff syndrome, NOS (Not Otherwise Specified) 726.12 Bicipital tenosynovitis 726.3 Enthesopathy of elbow region 726.31 Medial epicondylitis 726.32 Lateral epicondylitis 726.33 Olecranon bursitis 726.4 Enthesopathy of wrist and carpus 726.5 Enthesopathy of hip region 726.6 Enthesopathy of knee 726.61 Pes anserinus tendinitis 726.64 Tendinitis, patellar 726.65 Prepatellar bursitis 726.7 Metatarsalgia, NOS (Not Otherwise Specified) 726.71 Tendinitis, achilles 726.72 Tendinitis, tibialis 726.73 Calcaneal spur 727 Other disorders of synovium, tendon and bursa 727.0 Synovitis and tenosynovitis 727.00 Synovitis/tenosynovitis, unspec. 727.03 Trigger finger, acquired 727.04 de Quervain's disease 727.05 Tenosynovitis, hand/wrist 727.06 Tenosynovitis, foot/ankle 727.1 Bunion 727.4 Ganglion and cyst of synovium, tendon, and bursa 727.42 Ganglion, tendon sheath 727.43 Ganglion, unspec.
Sources: en.wikipedia.org
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.
The side chain enables reversible binding to albumin in the bloodstream, which protects the peptide from rapid renal clearance. This extends the interval between administrations compared with unmodified GLP-1.
No. It shares much of the native sequence but carries substitutions and an added side chain. These changes increase stability against enzymatic breakdown.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.